|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
These changes correlate with an enhanced expression of MICA and MICB in human MM cell lines and in primary malignant plasma cells, 2 ligands of the NK group 2D receptor (NKG2D)/CD314 activating receptor expressed in cytotoxic lymphocytes, rendering MM cells more sensitive to recognition, degranulation, and killing by NK cells.
|
31125275 |
2019 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
Biomarker |
BEFREE |
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
|
30396908 |
2019 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
Biomarker |
BEFREE |
We present comprehensive data on manufacturing development and clinical production of autologous NKG2D CAR T cells for treatment of acute myeloid leukemia and multiple myeloma (ClinicalTrials.gov Identifier: NCT02203825).
|
30180944 |
2018 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
Biomarker |
BEFREE |
<i>In vivo</i>, survival was significantly prolonged using CS1-NKG2D biAb in a xenograft NOD-SCID<sup>IL2γc-/-</sup> (NSG) mouse model engrafted with both human PBMCs and MM cell lines.
|
29769244 |
2018 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing.
|
28197392 |
2017 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
Biomarker |
BEFREE |
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
|
26071561 |
2015 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
Here, we show that these drugs can enhance the expression of the NKG2D and DNAM-1 activating receptor ligands MICA and PVR/CD155 in human MM cell lines and primary malignant plasma cells.
|
26269456 |
2015 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
In this article, we identify the signaling events underlying chemotherapy-induced NKG2D and DNAM-1 ligand expression on multiple myeloma (MM) cells.
|
24913980 |
2014 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
These results indicate that MM is associated with a significant reduction in NKG2D expression which may be contact-mediated rather than caused by soluble NKG2D ligands.
|
20024547 |
2010 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
Myeloma cell lines expressed NKG2D ligands.
|
18599182 |
2008 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
Biomarker |
BEFREE |
While ULBP2 binds the activating NK receptor NKG2D, the BB4 moiety binds to CD138, which is overexpressed on a variety of malignancies, including MM.
|
16210338 |
2006 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
AlteredExpression |
BEFREE |
They can be activated by cytokines such as interleukin (IL)-2, IL-12 and IL-15, express natural killer (NK) cell markers such as NKG2D and show cytotoxic activity against several tumour cells, including multiple myeloma.
|
16734623 |
2006 |
|
KLRC4-KLRK1
|
Multiple Myeloma
|
0.100 |
Biomarker |
BEFREE |
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
|
15328155 |
2005 |